Asparaginase Erwinia chrysanthemi as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia who have developed hypersensitivity to E. Coli-derived asparaginase

Lisa Figueiredo, Peter Cole, Richard Drachtman

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Asparaginase has been a mainstay of therapy in the treatment of acute lymphoblastic leukemia since the 1970s. There are two major preparations available and FDA approved in the United States today, one derived from Escherichia coli and the other from Erwinia chrysanthemi. Erwinia asparaginase is antigenically distinct from and has a considerably shorter biological half-life than E coli asparaginase. Erwinia asparaginase has been used in cases of hypersensitivity to E. Coli-derived asparaginases, which has been reported in up to 30% of patients. While PEG asparaginase is increasingly used in front-line therapy for ALL, hypersensitivity still occurs with this preparation, and a change to a non-cross-reactive preparation may be necessary.

Original languageEnglish (US)
Pages (from-to)227-234
Number of pages8
JournalExpert Review of Hematology
Volume9
Issue number3
DOIs
StatePublished - Mar 3 2016

Fingerprint

Pectobacterium chrysanthemi
Asparaginase
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Hypersensitivity
Escherichia coli
Erwinia
Therapeutics
Half-Life

All Science Journal Classification (ASJC) codes

  • Hematology

Keywords

  • Asparaginase
  • Hypersensitivity
  • Leukemia
  • Pancreatitis
  • Thrombosis

Cite this

@article{6dec85a1247b4a21b38ded189d27fa97,
title = "Asparaginase Erwinia chrysanthemi as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia who have developed hypersensitivity to E. Coli-derived asparaginase",
abstract = "Asparaginase has been a mainstay of therapy in the treatment of acute lymphoblastic leukemia since the 1970s. There are two major preparations available and FDA approved in the United States today, one derived from Escherichia coli and the other from Erwinia chrysanthemi. Erwinia asparaginase is antigenically distinct from and has a considerably shorter biological half-life than E coli asparaginase. Erwinia asparaginase has been used in cases of hypersensitivity to E. Coli-derived asparaginases, which has been reported in up to 30{\%} of patients. While PEG asparaginase is increasingly used in front-line therapy for ALL, hypersensitivity still occurs with this preparation, and a change to a non-cross-reactive preparation may be necessary.",
keywords = "Asparaginase, Hypersensitivity, Leukemia, Pancreatitis, Thrombosis",
author = "Lisa Figueiredo and Peter Cole and Richard Drachtman",
year = "2016",
month = "3",
day = "3",
doi = "10.1586/17474086.2016.1142370",
language = "English (US)",
volume = "9",
pages = "227--234",
journal = "Expert Review of Hematology",
issn = "1747-4086",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Asparaginase Erwinia chrysanthemi as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia who have developed hypersensitivity to E. Coli-derived asparaginase

AU - Figueiredo, Lisa

AU - Cole, Peter

AU - Drachtman, Richard

PY - 2016/3/3

Y1 - 2016/3/3

N2 - Asparaginase has been a mainstay of therapy in the treatment of acute lymphoblastic leukemia since the 1970s. There are two major preparations available and FDA approved in the United States today, one derived from Escherichia coli and the other from Erwinia chrysanthemi. Erwinia asparaginase is antigenically distinct from and has a considerably shorter biological half-life than E coli asparaginase. Erwinia asparaginase has been used in cases of hypersensitivity to E. Coli-derived asparaginases, which has been reported in up to 30% of patients. While PEG asparaginase is increasingly used in front-line therapy for ALL, hypersensitivity still occurs with this preparation, and a change to a non-cross-reactive preparation may be necessary.

AB - Asparaginase has been a mainstay of therapy in the treatment of acute lymphoblastic leukemia since the 1970s. There are two major preparations available and FDA approved in the United States today, one derived from Escherichia coli and the other from Erwinia chrysanthemi. Erwinia asparaginase is antigenically distinct from and has a considerably shorter biological half-life than E coli asparaginase. Erwinia asparaginase has been used in cases of hypersensitivity to E. Coli-derived asparaginases, which has been reported in up to 30% of patients. While PEG asparaginase is increasingly used in front-line therapy for ALL, hypersensitivity still occurs with this preparation, and a change to a non-cross-reactive preparation may be necessary.

KW - Asparaginase

KW - Hypersensitivity

KW - Leukemia

KW - Pancreatitis

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=84960220645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960220645&partnerID=8YFLogxK

U2 - 10.1586/17474086.2016.1142370

DO - 10.1586/17474086.2016.1142370

M3 - Review article

VL - 9

SP - 227

EP - 234

JO - Expert Review of Hematology

JF - Expert Review of Hematology

SN - 1747-4086

IS - 3

ER -